PCM
MRNA icon

Parsons Capital Management’s Moderna MRNA Stock Holding History

Parsons Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,760
Closed -$209K – 451
2024
Q2 		$209K Buy
+1,760
New +$223K 0.01% 425
2023
Q3 		– Sell
-1,760
Closed -$214K – 426
2023
Q2 		$214K Hold
1,760
– – 0.02% 410
2023
Q1 		$270K Hold
1,760
– – 0.02% 377
2022
Q4 		$316K Hold
1,760
– – 0.03% 350
2022
Q3 		$208K Hold
1,760
– – 0.02% 397
2022
Q2 		$251K Sell
1,760
-60
-3% -$8.58K 0.02% 370
2022
Q1 		$314K Sell
1,820
-460
-20% -$77.4K 0.02% 363
2021
Q4 		$579K Sell
2,280
-775
-25% -$227K 0.04% 288
2021
Q3 		$1.18M Buy
3,055
+1,505
+97% +$555K 0.09% 203
2021
Q2 		$364K Sell
1,550
-200
-11% -$35.7K 0.03% 337
2021
Q1 		$229K Buy
+1,750
New +$254K 0.02% 380

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parsons Capital Management's MRNA Position: Q3 2024 in Review

Parsons Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,760 shares — an estimated $209K sold.

Parsons Capital Management first reported a position in MRNA in Q1 2021 and held it in 11 quarters. The position peaked at $1.18M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Parsons Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Parsons Capital Management sold 1,760 Moderna shares in Q3 2024, an estimated $209K.
  • Parsons Capital Management first reported a position in Moderna in Q1 2021 and held it in 11 quarters.
  • Parsons Capital Management's Moderna position peaked at $1.18M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Parsons Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.